Early Trial: Daraxonrasib Plus Chemo Shrinks Pancreatic Tumors, 8.2% Complete Response
Daraxonrasib plus chemotherapy shrank pancreatic tumors in 60.7% of trial participants, with 8.2% achieving complete response, researchers reported Friday.
Early-stage clinical trial data for the drug daraxonrasib suggests a major advance in treating pancreatic cancer, according to research presented on Friday.
When administered alongside chemotherapy, the drug demonstrated an ability to shrink tumors in a majority of patients, with some cases showing complete clinical response.
Key Clinical Takeaways:
- Approximately 8% of patients in the study experienced a complete response, where tumors became undetectable on medical imaging.
- Nearly 90% of the 61 participants experienced stabilized tumor growth during the study period.
- The treatment targets specific RAS mutations commonly found in pancreatic tumors, offering a potential pathway for patients who have exhausted standard options.
Clinical Trial Outcomes for Advanced Pancreatic Cancer
The research, which focused on 61 patients recently diagnosed with advanced, metastatic pancreatic cancer, utilized a combination of daraxonrasib, gemcitabine, and nab-paclitaxel. Data reported by Investing.com indicates that the median progression-free survival reached 12.8 months, with a median follow-up period of 18.3 months. Among the participants, 60.7% showed a confirmed objective response, while 8.2% achieved a complete response, as reported by the study investigators at the EORTC-NCI-AACR Symposium in Barcelona.
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center described the current findings as highly encouraging, according to BBC News Türkçe. Daraxonrasib functions as a KRAS inhibitor, a class of drugs designed to block the specific mutations that drive tumor proliferation in most pancreatic cancer patients.
Because these same mutations are present in various other malignancies, including ovarian and lung cancers, the potential therapeutic scope of this inhibitor may extend well beyond pancreatic oncology.
While the initial data points to a potential shift in the standard of care, researchers caution that these results do not constitute a definitive cure. According to BBC News, medical professionals are monitoring patients to determine how long the therapeutic effects can be maintained. Although 90% of patients saw their tumor growth halted, the disease in pancreatic cancer typically remains aggressive, often returning after initial chemotherapy-induced shrinkage.

“onlarca yıldır sahip olunan en büyük ilerleme” Dr. Sam Godfrey of Cancer Research UK told BBC News, according to TRT Haber.
“This new drug has found a way to treat the untreatable. We are finally seeing progress in pancreatic cancer that has been long overdue.”
said Dr. Sam Godfrey of Cancer Research UK, as reported by BBC News. He emphasized that even when scans show no detectable cancer, the possibility of recurrence remains, necessitating longer-term observation to confirm the durability of these remissions.
Pancreatic cancer remains one of the most difficult malignancies to manage, characterized by the lowest survival rates among common cancers in the United Kingdom. Statistics from Cancer Research UK highlight the severity of the diagnosis, with approximately 11,500 new cases annually and 10,200 resulting deaths. Patients typically face a prognosis measured in months rather than years, making the 12.8-month median progression-free survival observed in this study a notable clinical finding.
Prof. Elena Garralda, president of EORTC, said that the combination therapy has the potential to extend life expectancy and increase the duration before tumors resume growth.
For patients facing such a diagnosis, early access to specialized oncology centers is often the most critical factor in managing symptoms and handling treatment protocols. Consulting with board-certified oncologists who specialize in gastrointestinal malignancies can help patients determine if they are candidates for emerging clinical trials or targeted inhibitor therapies.
“Bu sonuçlar heyecan verici. İki tedavinin birlikte uygulanması, hastaların yaşam süresini uzatabilir ve tümörlerin yeniden büyümeye başlamasına kadar geçen süreyi önemli ölçüde artırabilir” Prof. Elena Garralda, president of EORTC, said.
As the medical community continues to evaluate these findings, the focus remains on the Phase 3 RASolute 303 study. This ongoing trial is currently comparing the efficacy of daraxonrasib in combination with chemotherapy against standard chemotherapy regimens alone in treatment-naive metastatic patients. These results will be essential in clarifying the role of KRAS inhibitors in the wider field of metastatic pancreatic adenocarcinoma treatment.
Memorial Sloan Kettering Cancer Center traces its origins to the 1884 founding of New York Cancer Hospital, the nation’s first dedicated cancer hospital, where surgeon William B. Coley pioneered an early form of immunotherapy.
In 1945, Alfred P. Sloan and Charles F. Kettering established the adjacent Sloan-Kettering Institute for Cancer Research, applying industrial research techniques to oncology. The two entities formally merged in 1980, creating one of the 72 National Cancer Institute–designated Comprehensive Cancer Centers.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.